ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
1.015
-0.075 (-6.88%)
Nov 5, 2024, 3:49 PM EST - Market open
ProMIS Neurosciences Employees
As of December 31, 2023, ProMIS Neurosciences had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,742,832
Market Cap
20.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | 1 | 16.67% |
Dec 31, 2021 | 6 | 5 | 500.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Beyond Air | 107 |
Athira Pharma | 67 |
Pieris Pharmaceuticals | 50 |
Inspira Technologies Oxy B.H.N. | 42 |
VSee Health | 40 |
Palatin Technologies | 30 |
Tempest Therapeutics | 17 |
Onconetix | 12 |
PMN News
- 6 days ago - ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference - GlobeNewsWire
- 7 weeks ago - ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing - GlobeNewsWire
- 6 months ago - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire